Unknown

Dataset Information

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein.


ABSTRACT: BRAF is a serine/threonine kinase frequently mutated in human cancers. BRAFV600E mutated protein is targeted through the use of kinase inhibitors which are approved for the treatment of melanoma; however, their long-term efficacy is hampered by resistance mechanisms. The PROTAC-induced degradation of BRAFV600E has been proposed as an alternative strategy to avoid the onset of resistance. In this study, we designed a series of compounds where the BRAF kinase inhibitor encorafenib was conjugated to pomalidomide through different linkers. The synthesized compounds maintained their ability to inhibit the kinase activity of mutated BRAF with IC50 values in the 40-88 nM range. Selected compounds inhibited BRAFV600E signaling and cellular proliferation

SUBMITTER: Marini E 

PROVIDER: S-EPMC9736157 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature